Wegovy Cost in Delaware (2026): Prices, Insurance, Savings Programs

Wegovy contains semaglutide 2.4 mg and is injected once weekly under the skin as a GLP-1 receptor agonist. The FDA approved it for weight management in adults who have obesity (BMI of 30 or higher) or are overweight (BMI of 27 or higher) and have at least one weight-related health condition, such as type 2 diabetes or high blood pressure. Although Ozempic also uses semaglutide (at a 2.0 mg dose for type 2 diabetes treatment), Wegovy and Ozempic are distinct products despite sharing the same active ingredient.

The real cost question for a Delaware resident is rarely "what is the list price." It is which of four separate pricing pathways applies: commercial insurance with a manufacturer savings card, Delaware Medicaid with prior authorization, cash payment at a retail pharmacy, or a compounded semaglutide product from a licensed pharmacy. Each pathway has a different price, a different eligibility test, and a different level of regulatory oversight, and none of these figures are stable enough to quote without a date attached.

Direct answer: Wegovy's manufacturer-published list price (wholesale acquisition cost, or WAC) has been reported in the $1,300s per month for a 28-day supply of the prefilled pen; Delaware retail pharmacies generally price close to that figure for cash-paying customers because pharmacy markup on brand GLP-1 pens is typically small. Actual out-of-pocket cost for an individual patient depends on insurance formulary status, whether a manufacturer copay card applies, and whether the patient instead uses a compounded semaglutide product, which is a different, non-FDA-approved preparation typically priced far below the brand. Because pricing, formulary rules, and Medicaid policy change without notice, every dollar figure below should be re-verified against a current source before a patient acts on it.

What is established versus what needs local verification

Established and stable (federal/clinical facts):

• Semaglutide 2.4 mg (Wegovy) is FDA-approved for chronic weight management under specific BMI and comorbidity criteria.
• The drug is dosed on a titration schedule that increases over roughly 16 weeks before reaching the 2.4 mg maintenance dose.
• Compounded semaglutide is not an FDA-approved product; it is a preparation made by a licensed pharmacy under Sections 503A or 503B of the Food, Drug and Cosmetic Act, and its legal availability during periods when semaglutide is not on the FDA drug shortage list is narrower than when it is.
• Semaglutide is not a federally controlled substance, which is why telehealth-only prescribing (without a prior in-person exam) is generally permissible under standard DEA rules for non-controlled drugs.

Plausible but requiring verification for Delaware specifically:

• The exact current list price and typical Delaware retail cash price (these move periodically; treat any number as a snapshot, not a guarantee).
• Delaware Medicaid's specific prior authorization criteria, MCO contact numbers, and typical turnaround time.
• Whether a specific commercial plan in Delaware covers Wegovy, at what tier, and with what prior authorization requirements.
• Current pricing at any named compounding pharmacy or telehealth platform serving Delaware.
• Whether semaglutide currently appears on the FDA drug shortage list, since that status affects the legality of compounded versions.

Not established:

• That compounded semaglutide is bioequivalent, equally safe, or equally effective compared with FDA-approved Wegovy. It has not undergone FDA review for safety, purity, or efficacy.
• Any claim about a specific insurer's coverage decision that has not been confirmed directly with that insurer for the current plan year.

Brand-name Wegovy retail pricing in Delaware

Novo Nordisk sets a national list price (WAC) for Wegovy, and cash-pay pharmacy prices tend to track that figure closely because insurers, not pharmacies, negotiate most of the discount off list price. Delaware chain and independent pharmacies do not set materially different cash prices from national averages; small differences of $20 to $80 can occur based on dispensing fees. Patients paying cash should ask the pharmacy to check the price through a discount card program (for example GoodRx-type services) before paying full cash price, since modest per-fill savings are sometimes available. Any specific dollar figure quoted here should be confirmed at the pharmacy counter on the day of fill, because manufacturer list prices and pharmacy contracts change.

The FDA approved semaglutide 2.4 mg for chronic weight management in 2021 based on a clinical trial program that enrolled adults with obesity or overweight and a weight-related condition. Reported average weight loss in the pivotal 68-week trial was substantially greater with semaglutide than with placebo. The exact percentage figures commonly cited for this trial should be checked against the primary publication (NEJM) before being repeated as precise numbers in patient-facing material, since secondary summaries sometimes round or misstate results.

Delaware Medicaid coverage

Delaware Medicaid has historically covered GLP-1 receptor agonists for weight management with a prior authorization requirement, consistent with how most state Medicaid programs handle these drugs. Typical PA criteria across state Medicaid programs require documentation of BMI meeting FDA label thresholds and evidence of a prior attempt at lifestyle intervention, but the exact current Delaware Medicaid PA form, criteria, and copay amount should be confirmed directly with the Delaware Division of Medicaid and Medical Assistance (DMMA) or the patient's managed care organization, since these details change and were not independently verified for this article. Do not rely on a fixed copay figure or turnaround-time estimate without checking the current plan document.

Commercial insurance in Delaware

Coverage for anti-obesity medications varies substantially by employer and by plan year; some commercial plans exclude weight-management drugs entirely from the formulary, while others cover them on a specialty tier with prior authorization. National survey data has suggested that a minority of large employer plans explicitly covered anti-obesity medications as of a few years ago, and coverage has been reported to be expanding since a large cardiovascular outcomes trial (SELECT) found that semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with obesity and established cardiovascular disease, without diabetes (Lincoff AM, et al. N Engl J Med. 2023, https://www.nejm.org/doi/full/10.1056/NEJMoa2307563). That trial's population was adults with pre-existing cardiovascular disease and obesity, not the general weight-loss population, and its cardiovascular result does not automatically apply to a patient seeking Wegovy for weight loss alone. Patients denied coverage for weight-loss indication only, who also have established cardiovascular disease, may have a stronger case for appeal citing this trial, but a formulary decision made by a specific Delaware insurer should be confirmed directly with that insurer rather than assumed from this article.

Compounded semaglutide 2.4 mg

Compounded semaglutide is produced by licensed 503A or 503B pharmacies rather than manufactured by Novo Nordisk, and it is typically priced well below brand Wegovy because compounders are not recovering the cost of clinical trials, marketing, or an approved manufacturing process. The FDA has stated that compounding of a drug that is not in shortage is generally restricted, and semaglutide's compounding eligibility has shifted over time depending on its status on the FDA drug shortage list (https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm). Anyone considering a compounded product should check that status on the date of the prescription, not rely on an article's snapshot.

Compounded semaglutide has not been reviewed by the FDA for safety, purity, or effectiveness, and it has not been tested for bioequivalence against Wegovy (see FDA's general compounding guidance: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers). Dose strength and formulation (including use of salt forms not present in the FDA-approved product) can vary between compounders. A patient considering compounded semaglutide should confirm the pharmacy's state license, ask whether it compounds under USP sterile compounding standards, and ask for a certificate of analysis for the active ingredient. Switching between brand and compounded product, or adjusting dose independently, should only happen under direct prescriber supervision.

Manufacturer savings card

Novo Nordisk has historically offered a savings card that can reduce out-of-pocket cost for commercially insured patients whose plan covers Wegovy, subject to program terms, an eligibility requirement that the patient not be enrolled in Medicare, Medicaid, TRICARE, or another government health program, and a maximum savings cap that has changed over time. The exact current copay amount, cap, and terms should be confirmed on the manufacturer's savings program page at the time of enrollment rather than assumed from a prior year's terms. Some high-deductible health plans use "copay accumulator" or "copay maximizer" programs that prevent manufacturer card payments from counting toward the deductible; patients on an HDHP should ask their plan directly whether this applies before assuming the card will meaningfully lower total annual cost.

Telehealth prescribing

Semaglutide is not a federally controlled substance, so under standard DEA rules a prescriber generally does not need to conduct an in-person exam before writing an initial prescription, which is why telehealth-based Wegovy prescribing is available to Delaware residents through providers licensed in the state or practicing under an applicable interstate arrangement. Any specific platform's fees, shipping practices, or insurance-verification process should be confirmed directly with that platform, since these are business practices that change independent of any FDA or state rule.

Lowering out-of-pocket cost: a decision path, not a single tip

The lowest-cost path depends on the patient's coverage status, not on a universal "cheapest option":

• A patient with commercial insurance that covers Wegovy should first confirm formulary tier and prior authorization requirements, then apply the manufacturer savings card if eligible.
• A patient on Delaware Medicaid should confirm current PA criteria with their MCO before assuming denial or approval.
• A patient with no insurance coverage for the drug, or whose plan excludes anti-obesity medications, faces the highest cash exposure for brand Wegovy and is the group for whom compounded semaglutide's lower price becomes most relevant, with the tradeoff that the product is not FDA-reviewed.
• A patient whose plan denies weight-loss-indication coverage but who also has documented cardiovascular disease may have a distinct appeal argument based on the SELECT trial's cardiovascular outcome data, which should be raised with the prescriber for a formal letter of medical necessity rather than pursued informally.

Manufacturer patient assistance programs for uninsured patients below an income threshold have existed for Wegovy in the past; current eligibility rules and enrollment steps should be confirmed on the manufacturer's own program page rather than assumed from prior program terms.

Verification checklist: what is stable versus what you must re-check today

Use this before making a coverage or purchasing decision. Items in the left column rarely change; items on the right change often and must be confirmed on the day you act.

When to seek urgent or in-person care

Semaglutide has labeled warnings for pancreatitis, gallbladder problems, and thyroid C-cell tumors seen in rodent studies (though the relevance to humans remains unclear). A boxed warning prohibits use in people with personal or family histories of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2. If you experience severe belly pain, signs of pancreatitis, severe allergic reaction symptoms, or notice a new neck lump while taking Wegovy, seek immediate medical attention rather than stopping doses due to cost concerns. Decisions about switching between the brand-name and compounded versions, skipping dose escalation to reduce expenses, or stopping treatment altogether should only be made in consultation with your prescriber, not on your own.

References

1. U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
2. U.S. Food and Drug Administration. FDA drug shortages database (check current status before relying on compounding legality). https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
3. U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). N Engl J Med. 2023;389(24):2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

Other claims referenced in earlier drafts of this article regarding exact Delaware pharmacy pricing, specific Medicaid MCO phone numbers, employer coverage percentages, and quoted physician statements could not be independently verified against a primary source and have been removed or converted to general, hedged statements pending editorial and clinical review.